Multifunctional IgG/IgM antibodies and cellular cytotoxicity are elicited by the full-length MSP1 SumayaVac-1 malaria vaccine
Radical control of malaria likely requires a vaccine that targets both the asymptomatic liver stages and the disease-causing blood stages of the human malaria parasite Plasmodium falciparum. While substantial progress has been made towards liver stage vaccines, the development of a blood stage vacci...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2023
|
| In: |
npj vaccines
Year: 2023, Volume: 8, Pages: 1-17 |
| ISSN: | 2059-0105 |
| DOI: | 10.1038/s41541-023-00701-2 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41541-023-00701-2 Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s41541-023-00701-2 
|
| Author Notes: | Micha Rosenkranz, Kristin Fürle, Julia Hibbert, Anne Ulmer, Arin Ali, Thomas Giese, Antje Blank, Walter E. Haefeli, Ernst Böhnlein, Michael Lanzer and Richard Thomson-Luque |
| Summary: | Radical control of malaria likely requires a vaccine that targets both the asymptomatic liver stages and the disease-causing blood stages of the human malaria parasite Plasmodium falciparum. While substantial progress has been made towards liver stage vaccines, the development of a blood stage vaccine is lagging behind. We have recently conducted a first-in-human clinical trial to evaluate the safety and immunogenicity of the recombinant, full-length merozoite surface protein 1 (MSP1FL) formulated with GLA-SE as adjuvant. Here, we show that the vaccine, termed SumayaVac-1, elicited both a humoral and cellular immune response as well as a recall T cell memory. The induced IgG and IgM antibodies were able to stimulate various Fc-mediated effector mechanisms associated with protection against malaria, including phagocytosis, release of reactive oxygen species, production of IFN-γ as well as complement activation and fixation. The multifunctional activity of the humoral immune response remained for at least 6 months after vaccination and was comparable to that of naturally acquired anti-MSP1 antibodies from semi-immune adults from Kenya. We further present evidence of SumayaVac-1 eliciting a recallable cellular cytotoxicity by IFN-γ producing CD8+ T cells. Our study revitalizes MSP1FL as a relevant blood stage vaccine candidate and warrants further evaluation of SumayaVac-1 in a phase II efficacy trial. |
|---|---|
| Item Description: | Veröffentlicht: 09. August 2023 Gesehen am 27.09.2023 |
| Physical Description: | Online Resource |
| ISSN: | 2059-0105 |
| DOI: | 10.1038/s41541-023-00701-2 |